HC Wainwright & Co. reiterated coverage on Oramed Pharmaceuticals with a new price target
$ORMP
Biotechnology: Pharmaceutical Preparations
Health Care
HC Wainwright & Co. reiterated coverage of Oramed Pharmaceuticals with a rating of Buy and set a new price target of $32.00 from $17.00 previously